These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9571601)

  • 1. Neuroendocrine effect of a short-term treatment with DHEA in postmenopausal women.
    Rubino S; Stomati M; Bersi C; Casarosa E; Luisi M; Petraglia F; Genazzani AR
    Maturitas; 1998 Jan; 28(3):251-7. PubMed ID: 9571601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women.
    Stomati M; Rubino S; Spinetti A; Parrini D; Luisi S; Casarosa E; Petraglia F; Genazzani AR
    Gynecol Endocrinol; 1999 Feb; 13(1):15-25. PubMed ID: 10368794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women.
    Genazzani AD; Stomati M; Strucchi C; Puccetti S; Luisi S; Genazzani AR
    Fertil Steril; 2001 Aug; 76(2):241-8. PubMed ID: 11476767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine effects of different estradiol-progestin regimens in postmenopausal women.
    Stomati M; Bersi C; Rubino S; Palumbo M; Comitini G; Genazzani AD; Santuz M; Petraglia F; Genazzani AR
    Maturitas; 1997 Dec; 28(2):127-35. PubMed ID: 9522320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids.
    Genazzani AD; Stomati M; Bernardi F; Pieri M; Rovati L; Genazzani AR
    Fertil Steril; 2003 Dec; 80(6):1495-501. PubMed ID: 14667889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
    Labrie F; Bélanger A; Cusan L; Candas B
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral dehydroepiandrosterone restores ß-endorphin response to OGTT in early and late postmenopause.
    Giannini A; Genazzani AD; Napolitano A; Caretto M; Stomati M; Simoncini T; Genazzani AR
    Gynecol Endocrinol; 2019 Sep; 35(9):767-771. PubMed ID: 30935252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dehydroepiandrosterone on central and peripheral levels of allopregnanolone and beta-endorphin.
    Bernardi F; Casarosa E; Pluchino N; Palumbo M; Genazzani AD; Luisi S; Genazzani AR
    Fertil Steril; 2005 Apr; 83 Suppl 1():1161-8. PubMed ID: 15831289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women.
    Genazzani AR; Pluchino N; Begliuomini S; Stomati M; Bernardi F; Pieri M; Casarosa E; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2006 Nov; 22(11):627-35. PubMed ID: 17145649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal function under long-term raloxifene administration.
    Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency.
    Genazzani AR; Inglese S; Lombardi I; Pieri M; Bernardi F; Genazzani AD; Rovati L; Luisi M
    Aging Male; 2004 Jun; 7(2):133-43. PubMed ID: 15672938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary?
    Labrie F; Martel C; Balser J
    Menopause; 2011 Jan; 18(1):30-43. PubMed ID: 20683211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women.
    Harrington LB; Marck BT; Wiggins KL; McKnight B; Heckbert SR; Woods NF; LaCroix AZ; Blondon M; Psaty BM; Rosendaal FR; Matsumoto AM; Smith NL
    J Thromb Haemost; 2017 Jan; 15(1):80-90. PubMed ID: 27797446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women.
    Igwebuike A; Irving BA; Bigelow ML; Short KR; McConnell JP; Nair KS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):534-8. PubMed ID: 18029465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women.
    Florio P; Quirici B; Casarosa E; Lombardi I; Luisi M; Genazzani AD; Petraglia F; Genazzani AR
    Gynecol Endocrinol; 2001 Oct; 15(5):359-66. PubMed ID: 11727358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study.
    Caufriez A; Leproult R; L'Hermite-Balériaux M; Kerkhofs M; Copinschi G
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):716-24. PubMed ID: 23488643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
    Morales AJ; Haubrich RH; Hwang JY; Asakura H; Yen SS
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):421-32. PubMed ID: 9876338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.
    Labrie F; Bélanger A; Labrie C; Candas B; Cusan L; Gomez JL
    J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):57-69. PubMed ID: 17627814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.